Cargando…
COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
The COVID‐19 pandemic has unfolded to be the most challenging global health crisis in a century. In 11 months since its first emergence, according to WHO, the causative infectious agent SARS‐CoV‐2 has infected more than 100 million people and claimed more than 2.15 million lives worldwide. Moreover,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898934/ https://www.ncbi.nlm.nih.gov/pubmed/33577115 http://dx.doi.org/10.1096/fj.202002662R |
_version_ | 1783653969129635840 |
---|---|
author | Singh, Ramandeep Kang, Alisha Luo, Xiangqian Jeyanathan, Mangalakumari Gillgrass, Amy Afkhami, Sam Xing, Zhou |
author_facet | Singh, Ramandeep Kang, Alisha Luo, Xiangqian Jeyanathan, Mangalakumari Gillgrass, Amy Afkhami, Sam Xing, Zhou |
author_sort | Singh, Ramandeep |
collection | PubMed |
description | The COVID‐19 pandemic has unfolded to be the most challenging global health crisis in a century. In 11 months since its first emergence, according to WHO, the causative infectious agent SARS‐CoV‐2 has infected more than 100 million people and claimed more than 2.15 million lives worldwide. Moreover, the world has raced to understand the virus and natural immunity and to develop vaccines. Thus, within a short 11 months a number of highly promising COVID‐19 vaccines were developed at an unprecedented speed and are now being deployed via emergency use authorization for immunization. Although a considerable number of review contributions are being published, all of them attempt to capture only a specific aspect of COVID‐19 or its therapeutic approaches based on ever‐expanding information. Here, we provide a comprehensive overview to conceptually thread together the latest information on global epidemiology and mitigation strategies, clinical features, viral pathogenesis and immune responses, and the current state of vaccine development. |
format | Online Article Text |
id | pubmed-7898934 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78989342021-03-03 COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development Singh, Ramandeep Kang, Alisha Luo, Xiangqian Jeyanathan, Mangalakumari Gillgrass, Amy Afkhami, Sam Xing, Zhou FASEB J Reviews The COVID‐19 pandemic has unfolded to be the most challenging global health crisis in a century. In 11 months since its first emergence, according to WHO, the causative infectious agent SARS‐CoV‐2 has infected more than 100 million people and claimed more than 2.15 million lives worldwide. Moreover, the world has raced to understand the virus and natural immunity and to develop vaccines. Thus, within a short 11 months a number of highly promising COVID‐19 vaccines were developed at an unprecedented speed and are now being deployed via emergency use authorization for immunization. Although a considerable number of review contributions are being published, all of them attempt to capture only a specific aspect of COVID‐19 or its therapeutic approaches based on ever‐expanding information. Here, we provide a comprehensive overview to conceptually thread together the latest information on global epidemiology and mitigation strategies, clinical features, viral pathogenesis and immune responses, and the current state of vaccine development. John Wiley and Sons Inc. 2021-02-12 2021-03 /pmc/articles/PMC7898934/ /pubmed/33577115 http://dx.doi.org/10.1096/fj.202002662R Text en © 2021 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Reviews Singh, Ramandeep Kang, Alisha Luo, Xiangqian Jeyanathan, Mangalakumari Gillgrass, Amy Afkhami, Sam Xing, Zhou COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development |
title | COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development |
title_full | COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development |
title_fullStr | COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development |
title_full_unstemmed | COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development |
title_short | COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development |
title_sort | covid‐19: current knowledge in clinical features, immunological responses, and vaccine development |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898934/ https://www.ncbi.nlm.nih.gov/pubmed/33577115 http://dx.doi.org/10.1096/fj.202002662R |
work_keys_str_mv | AT singhramandeep covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment AT kangalisha covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment AT luoxiangqian covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment AT jeyanathanmangalakumari covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment AT gillgrassamy covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment AT afkhamisam covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment AT xingzhou covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment |